Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $925
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice TargetHot
Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $750 to $925.
Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $750 to $925.